MXPA03009124A - Empleo de derivados de pirazolinas en la elaboracion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares. - Google Patents
Empleo de derivados de pirazolinas en la elaboracion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares.Info
- Publication number
- MXPA03009124A MXPA03009124A MXPA03009124A MXPA03009124A MXPA03009124A MX PA03009124 A MXPA03009124 A MX PA03009124A MX PA03009124 A MXPA03009124 A MX PA03009124A MX PA03009124 A MXPA03009124 A MX PA03009124A MX PA03009124 A MXPA03009124 A MX PA03009124A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydro
- pyrazole
- trifluoromethyl
- aminosulfonylphenyl
- methyl
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims abstract description 10
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 9
- 150000003219 pyrazolines Chemical class 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 12
- -1 methoxy, trifluoromethoxy, methylsulfonyl Chemical group 0.000 claims abstract description 90
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 83
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 62
- 239000000460 chlorine Substances 0.000 claims abstract description 30
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 23
- 239000011737 fluorine Substances 0.000 claims abstract description 20
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 19
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims abstract description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 4
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 150000003857 carboxamides Chemical class 0.000 claims abstract description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims abstract description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims abstract description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims description 42
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 32
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000005764 inhibitory process Effects 0.000 claims description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 206010006895 Cachexia Diseases 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 9
- 208000008636 Neoplastic Processes Diseases 0.000 claims description 8
- 230000001855 preneoplastic effect Effects 0.000 claims description 8
- ZZMJXWXXMAAPLI-UHFFFAOYSA-N 4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-UHFFFAOYSA-N 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000005747 tumor angiogenesis Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 9
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 9
- 102000003390 tumor necrosis factor Human genes 0.000 claims 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- LLGLLZAAZOGDEB-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound FC1=CC(F)=CC=C1N1N=C(C(F)(F)F)CC1 LLGLLZAAZOGDEB-UHFFFAOYSA-N 0.000 claims 2
- SWAUQQYFPQVQSJ-UHFFFAOYSA-N 2-(3-methylphenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound CC1=CC=CC(N2C(CC(=N2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 SWAUQQYFPQVQSJ-UHFFFAOYSA-N 0.000 claims 2
- JBRFWCGJQZUHBW-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C=CC(Cl)=CC=2)N=C(C(F)(F)F)C1 JBRFWCGJQZUHBW-UHFFFAOYSA-N 0.000 claims 2
- KYDWPNBHFLBRIS-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C=CC(F)=CC=2)N=CC1 KYDWPNBHFLBRIS-UHFFFAOYSA-N 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- FRQSGXCNDIYEIH-UHFFFAOYSA-N 3-(2-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C(=CC=CC=2)F)CC(C(F)(F)F)=N1 FRQSGXCNDIYEIH-UHFFFAOYSA-N 0.000 claims 2
- UCLTWOHUTQRYOX-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(F)C=CC=2)CC(C(F)(F)F)=N1 UCLTWOHUTQRYOX-UHFFFAOYSA-N 0.000 claims 2
- DUWSUJBWSUSJSF-UHFFFAOYSA-N 3-(4-methylphenyl)-2-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(C)=CC=C1C1N(C=2C=CC(=CC=2)S(C)(=O)=O)N=C(C(F)(F)F)C1 DUWSUJBWSUSJSF-UHFFFAOYSA-N 0.000 claims 2
- ACXXZWIJKRQJLQ-UHFFFAOYSA-N 3-(4-methylphenyl)-2-(4-sulfamoylphenyl)-3,4-dihydropyrazole-5-carboxamide Chemical compound C1=CC(C)=CC=C1C1N(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C(N)=O)C1 ACXXZWIJKRQJLQ-UHFFFAOYSA-N 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- VTYPWKRHGVKCAN-UHFFFAOYSA-N 4-[3-(2,3-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=C(F)C=CC=2)F)CC(C(F)(F)F)=N1 VTYPWKRHGVKCAN-UHFFFAOYSA-N 0.000 claims 2
- WXELPGWWHJCPHS-UHFFFAOYSA-N 4-[3-(2,4-dichlorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)CC(C(F)(F)F)=N1 WXELPGWWHJCPHS-UHFFFAOYSA-N 0.000 claims 2
- ASUHJSUSKBNECS-UHFFFAOYSA-N 4-[3-(2-fluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=CC=CC=2)F)CC(C(F)(F)F)=N1 ASUHJSUSKBNECS-UHFFFAOYSA-N 0.000 claims 2
- FUKIEVBHHBTNDY-UHFFFAOYSA-N 4-[3-(2-methylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound CC1=CC=CC=C1C1N(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C(F)(F)F)C1 FUKIEVBHHBTNDY-UHFFFAOYSA-N 0.000 claims 2
- UXMSSKLTDLLVKZ-UHFFFAOYSA-N 4-[3-(3-chloro-4-fluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=C(Cl)C(F)=CC=2)CC(C(F)(F)F)=N1 UXMSSKLTDLLVKZ-UHFFFAOYSA-N 0.000 claims 2
- QAPXFHIPWJILOM-UHFFFAOYSA-N 4-[3-(4-methoxy-2-methylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound CC1=CC(OC)=CC=C1C1N(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C(F)(F)F)C1 QAPXFHIPWJILOM-UHFFFAOYSA-N 0.000 claims 2
- XMRZZVGLGSTXFW-UHFFFAOYSA-N 4-[5-methyl-3-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1C(C)=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C1C1=CC=C(C(F)(F)F)C=C1 XMRZZVGLGSTXFW-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- KOPFEFZSAMLEHK-UHFFFAOYSA-N pyrazolecarboxylic acid Natural products OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- NUUXNKLZACNVSR-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)-3,4-dihydropyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1N(C=2C(=CC(F)=CC=2)F)N=C(C(F)(F)F)C1 NUUXNKLZACNVSR-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- DIRCLGLKRZLKHG-UHFFFAOYSA-N 4-hydroxybenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(O)C=C1 DIRCLGLKRZLKHG-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- VMRBITBSIDDKSD-UHFFFAOYSA-N 5-methyl-3-(4-methylsulfonylphenyl)-2-phenyl-3,4-dihydropyrazole Chemical compound C1C(C)=NN(C=2C=CC=CC=2)C1C1=CC=C(S(C)(=O)=O)C=C1 VMRBITBSIDDKSD-UHFFFAOYSA-N 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 19
- 206010009944 Colon cancer Diseases 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 125000000565 sulfonamide group Chemical group 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 101150071146 COX2 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 2
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000000783 acetimidoyl group Chemical group C(C)(=N)* 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- QOCDZDDDUCWJFM-DUXPYHPUSA-N (e)-4-(2,4-difluorophenyl)-1,1,1-trifluorobut-3-en-2-one Chemical compound FC1=CC=C(\C=C\C(=O)C(F)(F)F)C(F)=C1 QOCDZDDDUCWJFM-DUXPYHPUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NYYLZXREFNYPKB-UHFFFAOYSA-N 1-[ethoxy(methyl)phosphoryl]oxyethane Chemical compound CCOP(C)(=O)OCC NYYLZXREFNYPKB-UHFFFAOYSA-N 0.000 description 1
- UKKALSJSKAHGTL-UHFFFAOYSA-N 2,2,2-trifluoro-n-phenylethanimidoyl chloride Chemical compound FC(F)(F)C(Cl)=NC1=CC=CC=C1 UKKALSJSKAHGTL-UHFFFAOYSA-N 0.000 description 1
- ZZMJXWXXMAAPLI-AWEZNQCLSA-N 4-[(3s)-3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1[C@H](C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-AWEZNQCLSA-N 0.000 description 1
- IKEURONJLPUALY-UHFFFAOYSA-N 4-hydrazinylbenzenesulfonamide;hydron;chloride Chemical compound [Cl-].NS(=O)(=O)C1=CC=C(N[NH3+])C=C1 IKEURONJLPUALY-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- ZZMJXWXXMAAPLI-CQSZACIVSA-N C1=CC(S(=O)(=O)N)=CC=C1N1[C@@H](C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1[C@@H](C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-CQSZACIVSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108010078546 Complement C5a Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100818A ES2174757B1 (es) | 2001-04-06 | 2001-04-06 | Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. |
| PCT/ES2002/000137 WO2002080909A1 (es) | 2001-04-06 | 2002-03-21 | Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03009124A true MXPA03009124A (es) | 2005-04-11 |
Family
ID=8497370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03009124A MXPA03009124A (es) | 2001-04-06 | 2002-03-21 | Empleo de derivados de pirazolinas en la elaboracion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040034082A1 (https=) |
| EP (2) | EP1516621A3 (https=) |
| JP (1) | JP4451599B2 (https=) |
| KR (1) | KR20040025912A (https=) |
| CN (2) | CN1299682C (https=) |
| AT (1) | ATE326966T1 (https=) |
| AU (1) | AU2002246152B2 (https=) |
| BR (1) | BR0208805A (https=) |
| CA (1) | CA2442974C (https=) |
| CY (1) | CY1105523T1 (https=) |
| DE (1) | DE60211681T2 (https=) |
| DK (1) | DK1384477T3 (https=) |
| ES (2) | ES2174757B1 (https=) |
| HU (1) | HUP0400918A3 (https=) |
| IL (1) | IL158269A0 (https=) |
| IS (1) | IS6973A (https=) |
| MA (1) | MA27019A1 (https=) |
| MX (1) | MXPA03009124A (https=) |
| NO (1) | NO20034470L (https=) |
| NZ (1) | NZ529304A (https=) |
| PL (1) | PL365220A1 (https=) |
| PT (1) | PT1384477E (https=) |
| RU (1) | RU2305545C2 (https=) |
| UA (1) | UA75402C2 (https=) |
| WO (1) | WO2002080909A1 (https=) |
| ZA (1) | ZA200308626B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077910A1 (en) * | 2004-02-16 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Pyrazoline derivatives useful for the treatment of cancer |
| ES2238923B1 (es) * | 2004-02-16 | 2006-11-01 | Laboratorios Del Dr. Esteve, S.A. | Nuevos derivados pirazolinicos sustituidos. |
| US7998996B2 (en) | 2004-02-17 | 2011-08-16 | Laboratorios Del Dr. Esteve S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
| EP1637522A1 (en) * | 2004-09-16 | 2006-03-22 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
| CA2556568A1 (en) * | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1749525A1 (en) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Combination of substituted pyrazolines and anti-addictive agent |
| WO2007009703A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | New formulations of substituted pyrazoline compounds |
| EP1746090A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios del Dr. Esteve S.A. | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| EP1849776A1 (en) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments |
| ES2327379B1 (es) * | 2005-07-15 | 2010-05-28 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos. |
| ES2319074B1 (es) * | 2005-07-15 | 2009-12-03 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principios activos. |
| ES2327203B1 (es) * | 2005-07-15 | 2010-06-07 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion. |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743892A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743642A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases |
| ES2336883B1 (es) * | 2005-07-15 | 2011-03-22 | Laboratorios Del Dr. Esteve, S.A. | Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre. |
| ES2326725B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada. |
| EP1743639A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazoline compounds for the treatment of coagulation related diseases |
| EP1749526A1 (en) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes |
| WO2007009706A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| EP1749527A1 (en) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome |
| EP1743889A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| EP1849784A1 (en) * | 2006-04-26 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Indoline-substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743637A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome |
| ES2316306B1 (es) * | 2005-07-15 | 2009-11-23 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos. |
| ES2326857B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico. |
| EP1743636A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Combination of a substituted pyrazoline compound and a drug used in food-related disorders |
| WO2007009699A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases |
| WO2007009701A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| EP1743643A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | New formulations of substituted pyrazoline compounds |
| KR101457637B1 (ko) * | 2012-10-24 | 2014-11-20 | 건국대학교 산학협력단 | 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물 |
| CN103664785A (zh) * | 2013-11-04 | 2014-03-26 | 南京大学 | 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 |
| WO2023043778A1 (en) * | 2021-09-14 | 2023-03-23 | Maverick Gold (Nv), Llc | Methods and systems for titling and trading alternative reserves |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0674624T3 (da) * | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| ES2141916T3 (es) * | 1993-11-30 | 2000-04-01 | Searle & Co | Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion. |
| US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| ES2137138B1 (es) * | 1998-05-29 | 2000-09-16 | Esteve Labor Dr | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos. |
| US6376519B1 (en) * | 1999-06-16 | 2002-04-23 | Temple University-Of The Commonwealth Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
-
2001
- 2001-04-06 ES ES200100818A patent/ES2174757B1/es not_active Expired - Fee Related
-
2002
- 2002-03-21 PT PT02714233T patent/PT1384477E/pt unknown
- 2002-03-21 NZ NZ529304A patent/NZ529304A/en unknown
- 2002-03-21 CA CA2442974A patent/CA2442974C/en not_active Expired - Fee Related
- 2002-03-21 DK DK02714233T patent/DK1384477T3/da active
- 2002-03-21 DE DE60211681T patent/DE60211681T2/de not_active Expired - Lifetime
- 2002-03-21 WO PCT/ES2002/000137 patent/WO2002080909A1/es not_active Ceased
- 2002-03-21 UA UA2003119998A patent/UA75402C2/uk unknown
- 2002-03-21 EP EP04030751A patent/EP1516621A3/en not_active Withdrawn
- 2002-03-21 HU HU0400918A patent/HUP0400918A3/hu unknown
- 2002-03-21 BR BR0208805-3A patent/BR0208805A/pt not_active IP Right Cessation
- 2002-03-21 ES ES02714233T patent/ES2264723T3/es not_active Expired - Lifetime
- 2002-03-21 RU RU2003132457/15A patent/RU2305545C2/ru not_active IP Right Cessation
- 2002-03-21 MX MXPA03009124A patent/MXPA03009124A/es active IP Right Grant
- 2002-03-21 JP JP2002578948A patent/JP4451599B2/ja not_active Expired - Fee Related
- 2002-03-21 IL IL15826902A patent/IL158269A0/xx unknown
- 2002-03-21 ZA ZA200308626A patent/ZA200308626B/en unknown
- 2002-03-21 EP EP02714233A patent/EP1384477B1/en not_active Expired - Lifetime
- 2002-03-21 KR KR10-2003-7013062A patent/KR20040025912A/ko not_active Ceased
- 2002-03-21 PL PL02365220A patent/PL365220A1/xx not_active Application Discontinuation
- 2002-03-21 CN CNB028098935A patent/CN1299682C/zh not_active Expired - Fee Related
- 2002-03-21 AT AT02714233T patent/ATE326966T1/de not_active IP Right Cessation
- 2002-03-21 CN CNA2005100713090A patent/CN1698602A/zh active Pending
- 2002-03-21 AU AU2002246152A patent/AU2002246152B2/en not_active Ceased
- 2002-03-21 US US10/312,193 patent/US20040034082A1/en not_active Abandoned
-
2003
- 2003-10-03 IS IS6973A patent/IS6973A/is unknown
- 2003-10-06 NO NO20034470A patent/NO20034470L/no not_active Application Discontinuation
- 2003-11-05 MA MA27382A patent/MA27019A1/fr unknown
-
2006
- 2006-08-03 CY CY20061101088T patent/CY1105523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03009124A (es) | Empleo de derivados de pirazolinas en la elaboracion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares. | |
| CA2333475C (en) | Derivatives of pyrazolines, their preparation and their application as medicaments | |
| KR100382619B1 (ko) | 2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도 | |
| CN100509811C (zh) | 氮杂吲哚 | |
| US5466823A (en) | Substituted pyrazolyl benzenesulfonamides | |
| TW201412744A (zh) | 吡唑并嘧啶化合物 | |
| WO2018019222A1 (zh) | 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 | |
| MXPA06003526A (es) | Derivados de pirazolo e imidazo-pirimidina. | |
| CN117088876A (zh) | 一种高活性Wnt通路抑制剂化合物 | |
| KR101789430B1 (ko) | Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 | |
| JP2022504982A (ja) | ＴＧＦ－βＲ１阻害剤としての化合物及びその応用 | |
| CN106459050A (zh) | 三环化合物以及jak抑制剂 | |
| KR101914161B1 (ko) | 카나비노이드 1 수용체 저해제로 작용하는 신규 화합물 | |
| Dahal et al. | 1, 3‐diarylpyrazolones as potential anticancer agents for non‐small cell lung cancer: Synthesis and antiproliferative activity evaluation | |
| Singh et al. | A comprehensive review on synthetic strategy and MOA of marketed drugs having therapeutically potential chemical entity pyrazole | |
| HK1067311B (en) | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | |
| HK1085671A (en) | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | |
| TW200808700A (en) | Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them | |
| KR20160059366A (ko) | 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| HK1151793B (en) | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |